source
- Viking Therapeutics’ VK2735 shows 17.7% weight loss in Phase 1 and maintains effect with less frequent dosingViking Therapeutics reported Phase 1 results for its injectable GLP-1/GIP dual agonist VK2735, showing an average 17.7% reduction in body weight after 21 weeks of weekly dosing in a placebo-control…
- AI becomes core to biopharma R&D, driving efficiency and faster drug developmentAI is now regarded as essential to everyday operations in the biopharma sector, helping to reduce the time and cost of drug development. Pfizer CEO Albert Bourla said AI played a key role in integ…